Flemming Steen Jensen files SEC Form 4 disclosures for Ascendis Pharma A/S. They have made 1 open-market trade across 1 company since 2026, most recently 2026-05-11.
CIK 0001965612
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ASND | SELL | 2026-05-11 | 2026-05-12 | $238.49 | $4.6M | +3.5% | -9.7% | +7.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.